β-defensin 37 Inhibitors
β-defensin 37 inhibitors are chemical compounds designed to interact specifically with β-defensin 37, a member of the defensin family of antimicrobial peptides. These inhibitors typically operate by binding to the active or binding sites of β-defensin 37, disrupting its biological function. Defensins, including β-defensin 37, are small, cysteine-rich peptides that play a crucial role in modulating the immune response and microbial defense. Structurally, β-defensin 37 is characterized by its conserved cysteine residues, which form disulfide bridges, stabilizing its three-dimensional structure. Inhibitors targeting β-defensin 37 are generally designed to interfere with these structural or functional regions, often by mimicking the natural substrates or by blocking critical interaction domains essential for its molecular activity. These inhibitors are typically studied through structural biology techniques like X-ray crystallography or NMR spectroscopy, which allow detailed visualization of the interactions between β-defensin 37 and its inhibitors.
Chemically, the inhibitors often comprise small molecules, peptides, or synthetic analogs that can precisely target the β-defensin 37's hydrophobic and hydrophilic domains. They may also utilize specific moieties capable of forming hydrogen bonds or hydrophobic interactions with the key residues of β-defensin 37, thereby impairing its structural integrity. Additionally, such inhibitors might modulate the folding of β-defensin 37 or disrupt the formation of its disulfide bridges. These mechanisms ensure that β-defensin 37 cannot perform its normal biological functions, resulting in changes in its molecular interactions. The development of these inhibitors involves rigorous processes of high-throughput screening, computational docking studies, and structure-activity relationship (SAR) analyses to ensure selectivity and specificity in their binding affinity to β-defensin 37.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
PARP inhibitor disrupting DNA repair. Veliparib indirectly inhibits β-defensin 37 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 37 transcription under conditions of cellular stress. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. Wortmannin indirectly hampers β-defensin 37, as PI3K/AKT signaling is implicated in the regulation of β-defensin 37 transcription by modulating specific transcription factors. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor targeting JAK-STAT signaling. Ruxolitinib indirectly suppresses β-defensin 37, as the JAK-STAT pathway regulates the transcription of β-defensin 37 by activating STAT proteins. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 37 by blocking NFAT activation, a key regulator of β-defensin 37 transcription in response to various stimuli. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor influencing the MAPK/ERK pathway. Selumetinib indirectly influences β-defensin 37 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 37 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 37, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 37. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 37 by altering histone acetylation, influencing the accessibility of the β-defensin 37 gene for transcription. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Wnt/β-catenin pathway inhibitor. XAV939 indirectly inhibits β-defensin 37, as the Wnt/β-catenin pathway is implicated in regulating β-defensin 37 expression by modulating the activity of specific transcription factors. | ||||||
Deferoxamine mesylate | 138-14-7 | sc-203331 sc-203331A sc-203331B sc-203331C sc-203331D | 1 g 5 g 10 g 50 g 100 g | $255.00 $1060.00 $2923.00 $4392.00 $8333.00 | 19 | |
HIF-1α inhibitor affecting the hypoxia pathway. Deferoxamine indirectly suppresses β-defensin 37, as HIF-1α enhances β-defensin 37 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $169.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 37, as TLR4 activation is known to upregulate β-defensin 37 expression through NF-κB and AP-1 signaling cascades. | ||||||